Ocular Therapeutix posts SOL-1 win
- Ocular Therapeutix said on February 17 that SOL-1, its phase 3 wet AMD trial, beat aflibercept 2 mg on the primary endpoint at week 36. - The headline number was 74.1% versus 55.8% for vision maintenance, with a 17.5-point risk difference and p=0.0006 after equal loading. - It matters because SOL-1 targets a superiority label in wet AMD, while SOL-R could turn durability into a filing package.
Retina drugs are a durability business now. The basic problem in wet age-related macular degeneration is not that doctors lack medicines that work — it’s that the medicines usually wear off fast enough to keep patients coming back for repeated eye injections. Ocular Therapeutix says its phase 3 SOL-1 trial just cleared a big hurdle by showing AXPAXLI beat standard aflibercept 2 mg on a superiority endpoint, not just a non-inferiority one. That is a more ambitious claim, and it lands in a market where “works about as well” is no longer enough. (ophthalmologytimes.com) ### What is AXPAXLI, exactly? AXPAXLI — also called OTX-TKI in the trial record — is an investigational intravitreal hydrogel that carries axitinib, a tyrosine kinase inhibitor aimed at VEGF-driven disease in the retina. The pitch is simple: put a longer-acting drug depot inside the e(ophthalmologytimes.com)cifically in treatment-naïve wet AMD. (clinicaltrials.gov) ### What did SOL-1 actually test? SOL-1 enrolled 344 evaluable, treatment-naïve wet AMD patients across more than 100 sites in the U.S. and Argentina. The design matters: everyone first got two aflibercept 2 mg loading injections, and only patients who hit a strong early response were randomized 1:1 to a single dose of AXPAXLI 0.45 mg or a single(clinicaltrials.gov) comparison — it was a head-to-head after the same setup. (ophthalmologytimes.com) ### Why is “superiority” a big deal? Because retina trials often aim for non-inferiority — basically, prove the new thing is not meaningfully worse while maybe offering convenience. SOL-1 was built to do more than that. The primary endpoint was the share of patients who maintained vis(ophthalmologytimes.com)riority label under FDA draft guidance for wet AMD therapies. (ophthalmologytimes.com) ### So what were the numbers? The topline readout was strong. At week 36, 74.1% of patients on AXPAXLI maintained vision versus 55.8% on aflibercept 2 mg, for a 17.5 percentage-point risk difference with p=0.0006. Ocular also said AXPAXLI showed either statistical significance or nume(ophthalmologytimes.com)ed results, not a full paper or conference dataset yet. (ophthalmologytimes.com) ### Did the effect hold up past week 36? Early signs say yes. In later discussion of the readout, investigators highlighted durability through week 52, with 65.9% of AXPAXLI patients maintaining vision versus 44.2% on aflibercept. They also pointed to better central subfield thickness(ophthalmologytimes.com) fewer extra injections, more staying power. (ophthalmologytimes.com) ### Why did Ocular choose this odd trial setup? Because the company is trying to prove durability cleanly. By giving both arms the same aflibercept loading phase first, SOL-1 asks a sharper question: once patients are stabilized, which single treatment keeps them (ophthalmologytimes.com)retina specialists actually think about maintenance. (ophthalmologytimes.com) ### What happens next? SOL-1 is only half the package. Ocular has said SOL-R — a separate phase 3 trial that compares AXPAXLI every 6 months against on-label aflibercept every 8 weeks, plus an aflibercept 8 mg masking arm — is meant to help support an NDA after positive SOL-1 and SOL-R results. SOL-R had reached its 555-patient randomization target by November 2025. (ophthalmologytimes.com) ### Bottom line This looks like a real win, not a cosmetic one. But the full value of the win depends on the missing pieces — complete safety data, full secondary endpoints, and whether SOL-R turns one strong readout into a filing-ready story. (ophthalmologytimes.com)
